NCT06662786 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06662786
Title	A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)
Acronym	OrigAMI-2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Janssen Research & Development, LLC
Indications	colorectal adenocarcinoma
Therapies	Oxaliplatin Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL

Additional content available in CKB BOOST